Generic Name and Formulations:
C1 esterase inhibitor (human) 2000 IU, 3000 IU; lyophilized pwd for SC inj after reconstitution; preservative-free.
CSL Behring, LLC
Indications for HAEGARDA:
Routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Adults and Children:
Rotate inj sites. Give by SC inj (eg, abdominal area, other SC sites). 60 IU/kg twice weekly (every 3 or 4 days).
Discontinue and treat if severe hypersensitivity reactions occur. Have epinephrine inj available. Risk of thromboembolism events. Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Pregnancy. Nursing mothers.
Inj site reaction, hypersensitivity, nasopharyngitis, dizziness.
To report infections that may have been transmitted by Haegarda, call (866) 915-6958.
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D